Aaliyah Washington

Results We evaluated paired cell-free DNA (cfDNA) and/or tissue specimens from 40 patients with KRAS mutant NSCLC (17), CRC (15), melanoma (4), or other cancers (4), treated with daraxonrasib as part of the phase 1/1b clinical trial NCT05379985. Genomic DNA extracted from these specimens was subjected to next-generation sequencing to identify potential resistance alterations.

Abstract Mechanisms of X chromosome dosage compensation have been studied extensively in three model organisms that represent distinct clades. The diversity within each clade as a function of sex chromosome evolution though is largely unknown. Here, we anchor ourselves to the nematode Caenorhabditis elegans, where dosage compensation is accomplished by an X chromosome specific condensin that belongs to the family of structural maintenance of chromosomes (SMC) complexes.

Abstract Mechanisms of X chromosome dosage compensation have been studied extensively in a few model species representing clades of shared sex chromosome ancestry. However, the diversity within each clade as a function of sex chromosome evolution is largely unknown.